Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
U.S. STOCKS ON THE MOVE-Macy's, American Eagle, Designer Brands
U.S. STOCKS ON THE MOVE-Copper miners, BKV, Kinetik
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
U.S. STOCKS ON THE MOVE-Lovesac, Hagerty, Biohaven
Biohaven drops as US FDA seeks more BHV-7000 safety data
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
RBC downgrades Biohaven to 'sector perform', shares fall
U.S. STOCKS ON THE MOVE-Williams-Sonoma, Kraft Heinz, Evommune
U.S. STOCKS ON THE MOVE-Revolution Medicines, Abercrombie & Fitch, Williams-Sonoma
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker
U.S. STOCKS ON THE MOVE-Semtech, Donaldson, Meta
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
Brief: Biohaven - Federal Court Confirms Ra Capital And Avilar Therapeutics "Misappropriated" Yale Trade Secret